Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Erkelenz – page 28

1 570 clinical trials in Erkelenz, Germany. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Erkelenz at a glance
1 570
clinical trials
  • Research sites0
Type of trial
Recruitment status
Quick filters

1 570 trials in Erkelenz

Open in trial search

Neuroblastoma

Recruiting

Study of Temozolomide, Topotecan, Bevacizumab, Irinotecan and Dinutuximab Beta in Patients with High-Risk Relapsed Neuroblastoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Bevacizumab
  • Sponsor:The University Of Birmingham

Study of Sacituzumab Tirumotecan and Pembrolizumab for Patients with Advanced or Recurrent Endometrial Cancer

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Pfizer Inc.

Osteoarthritis

Recruiting

Study on Treating Knee Osteoarthritis with Nasal Cartilage Implantation for Patients with Patellofemoral Osteoarthritis

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:N-Tec
  • Sponsor:Universitaetsspital Basel

Study of DNTH103 Treatment for Adults with Chronic Inflammatory Demyelinating Polyneuropathy: Comparing Effectiveness with Placebo

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:DNTH103
  • Sponsor:Dianthus Therapeutics Inc.

Study on Fruquintinib and Tislelizumab for Patients with Metastatic Colorectal Cancer Without Liver Metastases

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH

Study on the Safety and Effects of Iptacopan in Children with Paroxysmal Nocturnal Hemoglobinuria (PNH) Aged 2 to 17 Years

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Iptacopan Hydrochloride
  • Sponsor:Novartis Pharma AG

Study Comparing Ifinatamab Deruxtecan and Docetaxel for Patients with Advanced Prostate Cancer Resistant to Hormone Therapy

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate
  • Sponsor:Merck Sharp & Dohme LLC

COVID-19

Recruiting

Study of ibuzatrelvir tablets in non-hospitalized adults and adolescents with COVID-19 who are at high risk of developing severe illness

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Ibuzatrelvir
  • Sponsor:Pfizer Inc.

Study on Long-Term Safety and Efficacy of VX-670 for Adults with Myotonic Dystrophy Type I

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years
  • Substances:VX-670
  • Sponsor:Vertex Pharmaceuticals Inc.

Hepatoblastoma+1

Recruiting

Study on the Safety and Effectiveness of Patritumab Deruxtecan for Children with Relapsed or Refractory Hepatoblastoma and Rhabdomyosarcoma

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:0–17 years
  • Substances:Dexamethasone
  • Sponsor:Merck Sharp & Dohme LLC

Study on Letrozole and Gonadotropins for Women with Polycystic Ovary Syndrome (PCOS) to Improve Live Birth Rates

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years
  • Substances:Follitropin Alfa
  • Sponsor:Amsterdam UMC Stichting

Other cities in Germany

The busiest research cities in the country

All 505 cities in Germany

Clinical research in Erkelenz

What the registry says about research in the country

01 Breast Cancer Research

Innovative clinical trials focusing on triple-negative breast cancer evaluating the effectiveness of combining immunotherapy with traditional chemotherapy treatments. Studies aim to improve patient outcomes through personalized therapeutic approaches.

  • Triple-Negative Breast Cancer Treatment
  • Immunotherapy Integration
  • Event-Free Survival Assessment

Research explores novel combination therapies to enhance treatment efficacy.

02 Hormone Receptor Research

Studies examining personalized treatment strategies for HR+/HER2- breast cancer patients, comparing endocrine therapy combinations with standard chemotherapy approaches. Focus on long-term survival outcomes.

  • Endocrine Therapy Enhancement
  • Disease-Free Survival Analysis
  • Personalized Treatment Protocols

Investigation of targeted therapies to improve treatment effectiveness.

03 Advanced Treatment Studies

Research evaluating novel therapeutic approaches for HER2-negative breast cancer patients, particularly those at high risk of relapse after standard treatments. Focus on comparing innovative targeted therapies with conventional approaches.

  • High-Risk Patient Treatment
  • Relapse Prevention Strategies
  • Comparative Treatment Efficacy

Development of targeted solutions for challenging breast cancer cases.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.